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ABSTRACT Two distinct types of local anesthetics (LAs) have previously been found to block batrachotoxin (BTX)-modified
Na+ channels: type 1 LAs such as cocaine and bupivacaine interact preferentially with open channels, whereas type 2 LAs,
such as benzocaine and tricaine, with inactivated channels. Herein, we describe our studies of a third type of LA, represented
by tetracaine as a dual blocker that binds strongly with closed channels but also binds to a lesser extent with open channels
when the membrane is depolarized. Enhanced inactivation of BTX-modified Na+ channels by tetracaine was determined by
steady-state inactivation measurement and by the dose-response curve. The 50% inhibitory concentration (ICQ) was estimated
to be 5.2 pM at -70 mV, where steady-state inactivation was maximal, with a Hill coefficient of 0.98 suggesting that one tetracaine
molecule binds with one inactivated channel. Tetracaine also interacted efficiently with Na+ channels when the membrane was
depolarized; the IC50 was estimated to be 39.5 pM at +50 mV with a Hill coefficient of 0.94. Unexpectedly, charged tetracaine
was found to be the primary active form in the blocking of inactivated channels. In addition, external Na+ ions appeared to
antagonize the tetracaine block of inactivated channels. Consistent with these results, N-butyl tetracaine quaternary ammonium,
a permanently charged tetracaine derivative, remained a strong inactivation enhancer. Another derivative of tetracaine, 2-(di-
methylamino) ethyl benzoate, which lacked a 4-butylamino functional group on the phenyl ring, elicited block that was -1 00-fold
weaker than that of tetracaine. We surmise that 1) the binding site for inactivation enhancers is within the Na+ permeation
pathway, 2) external Na+ ions antagonize the block of inactivation enhancers by electrostatic repulsion, 3) the 4-butylamino
functional group on the phenyl ring is critical for block and for the enhancement of inactivation, and 4) there are probably
overlapping binding sites for both inactivation enhancers and open-channel blockers within the Na+ pore.
INTRODUCTION
Batrachotoxin (BTX) is an alkaloid neurotoxin that drasti-
cally alters the gating properties of voltage-dependent Na+
channels in excitable membranes. Activation is shifted by
-30-60 mV in a hyperpolarizing direction, whereas inac-
tivation is largely eliminated (for reviews see Khodorov,
1978; Catterall, 1980; Strichartz et al., 1987; Hille, 1992a).
However, several reports indicate that steady-state inactiva-
tion still occurs in BTX-modified Na+ channels in neuronal
cells (Zubov et al., 1984; Mozhayeva et al., 1986) and in
cardiac myocytes (Huang et al., 1987; Wasserstrom et al.,
1993). In a recent study, we found that the neutral local an-
esthetics (LAs) benzocaine and tricaine profoundly enhance
the inactivation of BTX-modified Na+ channels in rat pitu-
itary clonal GH3 cells, particularly near the potential range
between -90 and -40 mV (Wang and Wang, 1992a; 1994;
but see Schneider and Dubois, 1986, in frog nerve fibers).
Beyond this range, the block of benzocaine is weakened; this
observation is consistent with the notion that benzocaine
does not interact strongly with the resting and the open states
of BTX-modified Na+ channels.
In contrast to benzocaine and tricaine, a group of LAs
including QX-314 (a derivative of lidocaine), cocaine, bupi-
vacaine, and their derivatives (Moczydlowski et al., 1986;
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Wang, 1988) as well as hydrophilic and amphipathic qua-
ternary ammonium (QA) compounds (Moczydlowski et al.,
1986; Green et al., 1987; Wang et al., 1991) appear as open-
channel blockers. These drugs interact minimally with the
closed state of BTX-modified Na+ channels in GH3 cells.
Thus, there are two types of blockers for BTX-modified Na+
channels in GH3 cells: type 1 interacts preferentially with the
open state, and type 2 interacts preferentially with the closed,
inactivated state. The reason for these differential interac-
tions is not known. Zamponi and French (1993) recently
attempted to dissect these two modes of action on single
BTX-modified cardiac Na+ channels. These authors found
that phenol and diethylamine block closed and open chan-
nels, respectively. They suggested that neutral lidocaine
(equivalent to phenol) is the active form in binding with
closed BTX-modified cardiac Na+ channels, whereas
charged lidocaine (equivalent to diethylamine) is the active
form in binding with open channels; this hypothesis is com-
parable with that of Mocyzdlowski et al. (1986) for single
BTX-modified muscle Na+ channels. The latter authors dis-
covered that procaine can block both open and closed chan-
nels in lipid planar bilayers, a phenomenon similar to that
found for tetracaine (D. Bell and G. K. Wang, unpublished
data). The structural basis for the behavior of procaine and
tetracaine as dual blockers remains unclear.
In this study, we examined the effects of tetracaine on
macroscopic BTX-modified Na+ currents in GH3 cells to
verify that the neutral form is an active form in interacting
with closed channels. Tetracaine contains the entire back-
bone structure of benzocaine (minus two hydrogen atoms) as
well as a typical tertiary amine component found in most
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clinically used LAs (see structure 1, below). With a tertiary
amine, tetracaine can be positively charged when it is pro-
tonated. The ratio of the charged to the neutral form of tet-
racaine depends on the pH of the solution. In addition, a
quaternary derivative of tetracaine and a homolog lacking the
4-amino functional group on the phenyl ring were included
in this study. Our results lead us to conclude that charged
tetracaine is an active form that interacts strongly with in-
activated BTX-modified Na+ channels in GH3 cells. Fur-
thermore, the 4-amino functional group attached to the phe-
nyl ring of tetracaine appears to be critical for the potency
of tetracaine and for the enhancement of inactivation in BTX-
modified Na+ channels.
MATERIALS AND METHODS
Chemicals
Tetracaine (pY(. = 8.5) was obtained from Sigma Chemical Co. (St. Louis,
MO). A tetracaine homolog, 2-(dimethylamino) ethyl benzoate, was purchased
from Pfaltz and Bauer, Inc. (Waterbury, Cl). Tetracaine and its homolog were
dissolved in dimethylsulfoxide (DMSO) at 100-500 mM and maintained as
stock solutions at 4°C. BTX was provided by Dr. John Daly (National Institutes
of Health, Bethesda, MD) and was dissolved in DMSO at 0.5 mM.
Organic synthesis of N-butyl tetracaine QA
A 1:2 molar ratio of tetracaine base and 1-bromobutane (Aldrich, Milwau-
kee, WI) was mixed in 15 ml of absolute ethanol and refluxed at 85°C for
30 h. The reaction was stopped and excess ethanol was evaporated. The
jelly-like residue was washed several times with warm hexane to remove
the remaining starting reactants, and the product was dried under a vacuum.
The yield for N-butyl tetracaine QA was -90%, and the product was >97%
pure as judged with the thin layer chromatography system. N-Butyl tetra-
caine QA was dissolved in DMSO at 100 mM as a stock solution. The
chemical structures of tetracaine and its derivatives are shown below.
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Cell-culture and whole-cell voltage clamp
Rat pituitary clonal GH3 cells were maintained in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum and lx glu-
tamine as described by Cota and Armstrong (1989). The whole-cell variant
of the patch-clamp method (Hamill et al., 1981) was used to measure Na+
currents in GH3 cells. Two external solutions were used: 0-mM-Na+ so-
lution, which contained (in mM) 150 choline Cl, 0.2 CdCl2, 2 CaCl2, and
10 HEPES adjusted to pH 7.4 with tetramethyl hydroxide (TMA-OH), and
130-mM-Na+ solution, which contained (in mM) 20 choline-Cl, 130 NaCl,
0.2 CdCl2, 2 CaCl2, and 10 HEPES adjusted to pH 7.4 with TMA-OH.
Micropipettes were fabricated and had a tip resistance of --1 Mfl when
filled with a high Na+ solution containing (in mM) 0.005 BTX, 100 NaF,
30 NaCl, 10 EGTA, and 10 HEPES adjusted to pH 7.2 with CsOH. In some
experiments, the buffer of 10 mM HEPES at pH 7.2 was replaced with 10
mM 2-(N-morpholino)ethanesulfonic acid at pH 6.2 titrated with TMA-OH.
The junction potential of electrodes was nulled before seal formation. Liquid
junction potentials of 3.5 and 1.6 mV for the 130-mM-Na+ and 0-mM-Na+
external solutions (Wang and Wang, 1994), respectively, were not corrected
in this report. After the rupture of the patch membrane, repetitive pulses
(+50 mV with 50 ms at 2 Hz; Khodorov, 1978) for 5-10 min converted
normal channels into BTX-modified Na+ channels (60-95%), as judged by
the ratio of maintained (at 50 ms) and peak (at - 1 ms) Na+ currents. Because
of their fast kinetics, normal Na+ channels were not visible under our
voltage-clamp conditions with the slow time base. Drugs were applied to
cells via a series of narrow-bored capillary tubes positioned within 200 ,um
of the cell. The holding potential was set at -100 mV. Voltage-ramp pro-
tocols were created with pClamp software (Axon Instruments, Inc., Foster
City, CA). Leak and capacitance were subtracted by a homemade device.
All experiments were performed at room temperature (23 ± 2°C). At the
end of the experiments, the drift in the junction potential was generally <2
mV. Results of analyses are presented as mean ± SE.
RESULTS
Effects of tetracaine on steady-state inactivation
of BTX-modified Na+ channels
We have previously characterized the steady-state inactiva-
tion (hoo) of unmodified and BTX-modified Na+ channels in
GH3 cells (Wang and Wang, 1992a). Our results showed that
a significant number of BTX-modified Na+ channels were
inactivated near -70 mV (e.g., Fig. 1 A; Fig. 2, 0). To de-
termine whether tetracaine interacts with this closed state, we
measured the h., parameter with various prepulse potentials
in the absence and presence of 30 p,M tetracaine. Fig. 1
shows the current traces at +50 mV before and after 30 ,tM
tetracaine treatment with a prepulse of -170 mV (Fig. 1 B)
and -70 mV (Fig. 1 C) for 5 s. With the - 170-mV prepulse,
-50% of the current was inhibited by 30 ,M tetracaine; this
result suggested that tetracaine may interact with the closed
(possibly resting) state of BTX-modified Na+ channels al-
most as effectively as with open channels at +50 mV. There
was no apparent time-dependent block of Na+ currents by
tetracaine, a finding distinctly different from those obtained
with open-channel blockers such as cocaine and bupivacaine
(Wang and Wang, 1992b). These open-channel blockers elic-
ited a significant time-dependent block ofNa+ currents under
the same pulse protocol. This result (Figs. 1 B and 2) is
consistent with the notion that the degree of resting tonic
block by tetracaine at voltages between -130 and -170 mV
is substantial. Alternatively, tetracaine could elicit an ex-
tremely fast block ofNa+ currents that reaches its completion
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FIGURE 1 BTX-modified Na+ currents before and
after external application of 30 p,M tetracaine. (A) Con-
trol current traces at +50 mV were recorded with pre-
pulses of -170 mV (trace 1) and -70 mV (trace 2).
Notice that trace 2 in (A) consisted of fast and slow
rising phases. Tetracaine was then applied externally at
a concentration of 30 ,uM for 2-3 min and the current
traces at +50 mV were again recorded and super-
imposed with the drug-free record with a - 170-mV
prepulse (trace 1, B) or with a -70-mV prepulse
(trace 2, C).
A 1
-70 mV V
-170 mV t
within the first 15 ms of depolarization. This possibility is
less likely because an on-rate constant of tetracaine reaching
about >1.0 X 107 M` s-1 would be required. Most LAs
characterized as open-channel blockers have an on-rate con-
stant of 60 1.0 X 105 M-1 s-' (e.g., Wang, 1988).
With the -70-mV prepulse for 5 s, more than 80% of Na+
currents were initially blocked when tested at +50 mV (Fig.
1 C); the currents then rose slowly and eventually reached
steady state. Fig. 2 shows the hoo curve at various prepulse
voltages. The amplitudes of the initial fast component ofNa+
currents were measured at +50 mV with each prepulse po-
tential and were normalized with respect to the current am-
plitude measured with a prepulse of -170 mV. Clearly, the
block of tetracaine is maximal at -70 mV (Fig. 2, 0), in-
dicating that inactivated channels have the highest affinity
toward tetracaine. The potency of tetracaine was directly
measured as described next.
Concentration-dependent block of BTX-modified
Na+ channels by tetracaine
The dose-response relation for tetracaine was determined by
a method similar to that used previously for benzocaine
(Wang and Wang, 1994). Briefly, the inhibition of BTX-
modified Na+ currents at a test pulse of +50 mV was meas-
ured in the presence of tetracaine at concentrations ranging
from 1 to 300 ,uM. With a 5-s, -70-mV prepulse, Na+ cur-
rents activated by the test pulse again showed a biphasic
pattern (Fig. 3). As the tetracaine concentration was in-
creased, the fast rising phase, which presumably represented
the population of resting Na+ channels free of bound drug,
was progressively reduced. The initial inhibition of Na+ cur-
rents was measured, normalized, and plotted against the tet-
racaine concentration. This dose-response curve yielded an
apparent inhibitory concentration (IC50) of 5.2 ± 0.2 ,uM
(n = 5) at -70 mV (Fig. 4, 0). The kinetics of the second
rising phase, which represented the reopening of the inac-
tivated channels, were also concentration dependent. The
current rose more slowly to reach steady state as the tetra-
caine concentration increased. The good fit of the data from
-70 mV (Fig. 4, 0; Hill coefficient 0.98 ± 0.02) with the
Langmuir isotherm demonstrates that one tetracaine mole-
cule blocks one BTX-modified Na+ channel at this voltage.
With a prepulse of -170 mV, no second rising phase was
apparent at concentrations between 3 and 300 ,M, nor was
a time-dependent block observed at the test pulse (Fig. 3 B).
B
0.7nA L
0.4 s
C
k+30 iM
2
+30 ItM
-70 mV
-170 mV
The dose-response relation suggested that the tonic block at
-170 mV is similar to the block of open channels at +50
mV, a finding predicted by the hoo measurement. The dose-
response curve yielded an IC50 value of 39.5 ± 2.5 p,M
(n = 5; Fig. 4, 0) for tetracaine block at +50 mV, with a
Hill coefficient of 0.94 ± 0.05; this result again suggested
that one tetracaine molecule probably blocks one channel. At
this voltage, however, a fraction of the open channels could
become inactivated and subsequently stabilized by tetracaine
binding. Some of the open channels were probably blocked
by tetracaine in their open conformation. Hence, the IC50
might reflect the potency of tetracaine for more than one
channel conformation at this voltage.
Concentration-dependent block of BTX-modified
Na+ channels by tetracaine under
voltage-ramp conditions
Using a voltage-ramp protocol, we directly characterized the
voltage-dependent block ofNa+ currents by tetracaine. BTX-
modified Na+ currents were activated by a ramp protocol
from -130 to +50 mV with a ramp of 15- or 60-s duration.
The channel activation threshold, although varying from cell
to cell, generally occurred around -85 to -70 mV. After
reaching threshold voltages, Na+ currents rose almost lin-
early. In the presence of tetracaine, the currents generated by
the voltage-ramp protocol were inhibited in a concentration-
dependent manner (Fig. 5 A). The lack of significant dif-
ferences in current traces with either a 15- or a 60-s ramp
duration (data not shown) suggested that a quasi-steady state
of block by tetracaine was reached when channels were fully
activated (' -40 mV). From -50mV to +50 mV, the block
by tetracaine was clearly voltage dependent. The stronger
block by tetracaine at -50mV than at +50mVwas expected
from the hoo measurement and the dose-response curve de-
termined by the voltage-step method. Below -50 mV, the
block appeared to level off (Fig. 5 B) and then decreased at
the more negative potential. This result may have been due
in part to the higher error associated with small currents and
in part to the nonsteady-state condition in the voltage-ramp
protocol while the channels were at the activation threshold
(see Discussion). Despite this drawback, this protocol, with
its wide voltage range, is useful in the direct comparison of
the potency of tetracaine under various conditions that will
be described next.
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FIGURE 2 Effect of tetracaine on the steady-state inactivation of BTX-
modified Na+ channels. Normalized Na+ currents were plotted against pre-
pulse voltages. The current amplitudes at the first 15-30 ms of a +50-mV
test pulse, with various prepulse voltages of 5 s (as shown in Fig. 1), were
measured and normalized against the control-current amplitude with a
- 170-mV prepulse before external tetracaine application. Data were pooled
from five separate cells with (0) or without (0) external 30 ,uM tetracaine.
pH,-dependent block of BTX-modified Na+
channels by tetracaine
Changing the pH of the internal solution (pHi) alters the
intracellular concentration of the charged and neutral forms
of tetracaine, which has a pKY value of 8.5. The neutral form
accounts for -5.3% of the total intracellular tetracaine con-
centration at pHi 7.2 and for -0.5% (a 10-fold reduction) at
pHi 6.2. If only the neutral form of intracellular tetracaine
were active in blocking the inactivated BTX-modified Na+
channel, the potency of tetracaine would decrease at an in-
ternal pH of 6.2. Fig. 6 shows that the opposite is the case.
Within the range -65-+50 mV, more currents were inhib-
ited by tetracaine at pHi 6.2 (Fig. 6 B). In addition, a stronger
rectification of current at 0 to +50 mV, which is typical for
open-channel blockers, was evident. This result suggested
that the charged form of tetracaine is a dual blocker that
behaves as an inactivation enhancer at -50mV and may also
behave as an open-channel blocker when the membrane is
depolarized.
Quantitatively, there were only small changes in the pro-
tonated tetracaine concentration of the internal solution when
the pHi was lowered from 7.2 to 6.2 (94.7% vs. 99.5%, a <5%
increase). It was puzzling, then, to observe that lowering
of the pH1 to 6.2 gave rise to such an increase in tetra-
caine potency (Fig. 6B). We will return to this point in the
Discussion section.
Antagonistic effects of external Na+ ions on
tetracaine block
External Na+ ions reduce the potency of open-channel block-
ers such as QX-314, cocaine, and QA compounds (Wang,
1988; Wang et al., 1991) but have no effect on the potency
of the neutral inactivation enhancer benzocaine (Wang and
Wang, 1994). It was suggested that electrostatic repulsion
between inflowing Na+ ions and charged LAs might be the
cause for the observed reduction in LA affinity (Wang,
1988). To assess this notion, we raised the external Na+ con-
centration and measured the blocking effects of tetracaine.
Fig. 7, A and B, shows that Na+ ions significantly reduced
the potency of tetracaine at voltages between -75 mV and
+50 mV. It is interesting that very little inhibition of Na+
currents occurred within the voltage range for channel ac-
tivation (-85--65 mV). For example, at -70 mV fewer
than 40% of channels were blocked (Fig. 7 C). The reason
for this phenomenon is not clear, but a similar trend was
found in the absence of external Na+ ions. In any event,
reduction of tetracaine potency at voltages near -70 mV by
external Na+ ions is consistent with the ideas that the charged
form of tetracaine is responsible for the enhancement of in-
activation and that electrostatic repulsion between inflowing
Na+ ions and charged tetracaine is the cause for the decrease
in tetracaine affinity. It should be noted here that external
Na+ ions probably also reduced the potency of tetracaine's
interaction with Na+ channels when the membrane was de-
polarized. At +50 mV, <30% of Na+ current was blocked
in the presence of 130 mM external Na+ ions (Fig. 7 B),
whereas >50% was blocked in the absence of external Na+
ions for the same cell (Fig. 7 A).
Quaternary derivative of tetracaine as an
inactivation enhancer
Because both types of experiments shown in Figs. 6 and 7
suggested that the charged form of tetracaine is an inacti-
vation enhancer, we synthesized a quaternary derivative of
tetracaine (N-butyl tetracaine QA) and tested its blocking
effect. Like most QA blockers, N-butyl tetracaine QA when
applied externally inhibited BTX-modified Na+ currents
with much slower kinetics than its tertiary amine counterpart;
as a result, steady-state block could not be reached within 2
min. To facilitate the membrane penetration of charged
N-butyl tetracaine QA, we applied 200 ,uM externally. Fig.
8 shows the slow action of this drug. It took more than 10
min to block most of the Na+ current; the block of Na+
currents by 200 ,uM N-butyl tetracaine QA for 10 min, how-
ever, was nearly equivalent to that by 100-300 p,M tetracaine
(Fig. 5 A). The washout of the drug was extremely slow and
only partially reversible. This observation suggested that
most of N-butyl tetracaine QA was trapped within GH3 cells
after prolonged incubation, as has been noted for other am-
phipathic QA compounds tested in this system. Treatment of
N-butyl tetracaine QA also elicited a strong block of Na+
currents at the depolarized potentials. Current rectification
was evident at voltages between -10 and +50 mV after 5
min of QA treatment. This rectification was probably due to
the tetracaine QA binding site located within the membrane
electric field.
Effects of the tetracaine homolog
2-(dimethylamino) ethyl benzoate
Previous studies had suggested that the four-amino group in
the structure of benzocaine was important for enhancing the
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FIGURE 3 Inhibition of BTX-modified Na+
currents by various concentrations of tetracaine.
Currents were activated by a test pulse of +50
mV with a prepulse (Epp) of -70 mV (A) or
-170 mV (B) for 5 s. Current traces were su-
perimposed before and after drug application for
comparison. Tetracaine (at the concentration in-
dicated) was applied for 2-3 min while the cell
was held at -100 mV. With an Epp of -70 mV,
a biphasic rising pattern of Na+ current was ap-
parent (A), whereas only a rapid rising phase, too
fast to be recorded, was present with an Epp of
-170 mV (B). Both (A) and (B) were recorded
from the same cell.
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FIGURE 4 Dose-response curve for tetracaine block of BTX-modified
Na+ currents. The amplitudes of the fast rising phase of BTX-modified Na+
currents (shown as in Fig. 3 A) at various tetracaine concentrations were
measured, normalized with respect to the control-current amplitude, and
plotted against the tetracaine concentration (0, n = 5). The solid line rep-
resents the best fit of the data with a Hill coefficient of 0.98 ± 0.02. The
steady-state currents maintained at the end of the test pulse of +50 mV
were analyzed (in a manner similar to that described in Fig. 3 B) with a
prepulse of -170 mV and were plotted against the tetracaine concentration
(, n = 5). The Hill coefficient was 0.94 ± 0.05 for this set of data.
inactivation of Na+ channels (Wang and Wang, 1994). To
assess this possibility, we tested a structure-related homolog
of tetracaine under voltage-ramp conditions. This homolog
lacks the butylated four-amino group in the phenyl ring (see
structure. Fig. 9 shows that 1.5 mM or 5 mM 2-(diethyl-
amino) ethyl benzoate was much less active than 100 ,uM
tetracaine in blocking Na+ currents. There may have been
some interactions of the inactivated Na+ channels and 1.5
mM 2-(dimthylamino) ethyl benzoate, given that more block
was found near -50 mV than other voltages. Nevertheless,
the IC50 of this block was about two orders of magnitude
larger than that of tetracaine (-1.5 mM vs. '10 ,uM at -50
mV). This result suggested that the [-NH(-C4H9)] func-
tional group attached to the phenyl ring of tetracaine in-
creases the potency by about two orders of magnitude at -50
mV.
DISCUSSION
The main quest of this investigation was to confirm that only
the neutral form of tetracaine enhances the inactivation of
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FIGURE 5 Voltage dependence of tetracaine block in BTX-modified
Na+ channels under voltage-ramp conditions. Na+ currents (A) were acti-
vated by a voltage-ramp protocol from -130 to +50 mV linearly for 15 s.
Current traces shown from -100 to +50 mV were superimposed with or
without tetracaine. Tetracaine (at the concentrations indicated) was applied
externally for 2-3 min while the cell was held at -100 mV. The amplitudes
of Na+ currents in (A) at various tetracaine concentrations at each voltage
were measured, normalized with respect to the control-current amplitude,
and plotted against the voltage (B). Because of the relatively small current
amplitude below -50 mV, a higher level of noise was produced after nor-
malization. Results were similar in six other cells.
BTX-modified Na+ channels. Our results show that, contrary
to this hypothesis, the charged form of tetracaine is mostly
responsible for enhancing inactivation at pH 7.2. The dose-
response curve indicates that there is one single binding site
for tetracaine in the inactivated channel. This binding site is
probably located within the Na+ permeation pathway. On the
basis of structure-activity studies, we propose that the four-
amino group attached to the phenyl ring of tetracaine is im-
portant for binding as well as for promoting the inactivation
( ( L-1
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FIGURE 6 Dependence of tetracaine block on pH; in BTX-modified Na+
channels under voltage-ramp conditions. Tetracaine at a concentration of 30
,uM was applied externally while the cell was held at -100 mV (A). The
intracellular pHK was assumed to be 6.2, the same as the pH value for the
pipette solution (see Materials and Methods). The amplitudes of Na+ cur-
rents in (A) at each voltage were measured, normalized with respect to the
control-current amplitude, and plotted against the voltage (B). Results were
similar in four other cells. The normalized current at pH. 7.2 was taken from
Fig. 5 B, which was also treated with 30 ,uM tetracaine. Because this cell
with a pHK of 6.2 was activated near -70 mV, normalization could not be
performed below -65 mV.
of BTX-modified Na+ channels. In the remainder of this
article, we will discuss in detail how these conclusions are
derived.
Is the neutral form of tetracaine the only
active form?
Several lines of evidence demonstrate that the neutral form
of tetracaine is not the primary active form for the blocking
action of tetracaine. First, lowering of the internal pH from
7.2 to 6.2, which decreases 10-fold the concentration of the
neutral form of intracellular tetracaine, does not reduce its
blocking potency. Instead, inactivation is further enhanced
by lowering of the intracellular pH, a result indicating that
the charged form is active. Second, raising of the external
Na+ concentration significantly reduces the potency of tet-
racaine in enhancing inactivation. This result would not be
expected if the neutral form were the primary active form.
Third, the quaternary derivative of tetracaine, N-butyl tet-
racaine QA, is as potent as tetracaine itself in enhancing
inactivation. Because N-butyl tetracaine QA is permanently
charged, there is no reason to believe that charged tetracaine
is not active.
Together, these results are inconsistent with the hypothesis
that the neutral form of tetracaine is the main active form.
However, is it possible that the neutral form is active, al-
though with a lesser affinity than that of the charged form?
Our data do not allow us to address this question. Given that
benzocaine is a neutral inactivation enhancer, it is reasonable
to assume that the neutral form of tetracaine is active. The
persistent tonic block ofNa+ channels at a relatively negative
potential of <-130 mV suggests that neutral tetracaine can
probably reach its binding site when the channel is closed.
However, bound neutral tetracaine can easily be protonated
by external hydrogen ions (Schwarz et al., 1977). To address
the potency of neutral tetracaine will require systematic al-
teration of internal and external pH. In any event, our results
clearly show that charged tetracaine is active, even more so
than its neutral counterpart. It is noteworthy that there is a
disproportional increase of tetracaine potency when the pHi
was lowered from 7.2 to 6.2 (an increase of less than 5% in
the charged form). This phenomenon, however, can be ex-
plained if we assume that the pK4 value for tetracaine near
its binding site is less than the aqueous value of 8.5. This
assumption is likely to be true, given that the measured pKa
of another LA, cocaine, near its binding site in single BTX-
modified Na+ channels is -7.1 or 1.4 units lower than its
aqueous value of 8.5 (Nettleton and Wang, 1990).
Is the tetracaine binding site within the
permeation pathway?
The conclusion that the charged form of tetracaine can en-
hance inactivation suggests that tetracaine binding involves
a hydrophilic binding domain encompassing the tertiary
amine component. The receptor for this putative hydrophilic
binding domain may be located within the Na+ permeation
pathway, given that the external Na+ ions reduce the binding
affinity of LAs significantly. As described in this report and
in other studies with and without BTX presence (Cahalan and
Almers, 1979; Barber et al., 1992; Zamponi et al., 1993b),
Na+ ions can reduce the potency of charged LAs, probably
through electrostatic repulsion. If the reduction of LA po-
tency is attributable to conformational changes at the LA
binding site, then one would expect to observe a similar re-
duction in potency with a neutral LA. No such effect was
found; benzocaine, a neutral inactivation enhancer, was not
repulsed by external Na+ ions (Wang and Wang, 1994). It is
interesting that, near the channel activation threshold (i.e.,
-85 to -60 mV), external Na+ ions are extremely effective
in "knocking out" bound tetracaine. This result may be ex-
plained by the following. 1) When external Na+ ions enter
the membrane electric field within the Na+ pore, they are
forcefully driven in by the negative electric potential, and the
inflowing Na+ ions then repulse the bound charged tetra-
caine. 2) The bound charged tetracaine is also within the
electric field and is forcefully driven out of the pore by this
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negative potential. In other words, at -85--60 mV, the
membrane potential favors the entry of external Na+ ions into
the pore and the exit of bound charged tetracaine.
It is noteworthy that steady-state inactivation with and
without tetracaine (Fig. 2) occurs maximally at -70 mV. We
FIGURE 9 Effect of 2-(dimethylamino) ethyl benzoate on BTX-modified
Na+ currents. 2-(Dimethylamino) ethyl benzoate was applied externally at
1.5 or 5 mM in the solution without external Na+ ions for 2-3 min (A).
Currents were superimposed for comparison. The amplitude ofNa+ currents
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current amplitude, and plotted against the voltage (B). The potency of 2--
(dimethylamino) ethyl benzoate was about two orders of magnitude lower
than that of tetracaine (Fig. 5 A). Results were similar in four other cells.
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measured by the voltage-step method at -70 mV (Fig. 4), to
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highest affinity for tetracaine. Why, then, is the potency of
tetracaine weakened at voltages between -85 and -60 mV,
as measured by the voltage-ramp protocol (Fig. 5 B)? The
reason for this discrepancy is probably related to the blocking
kinetics of tetracaine. We found that at -70 mV it took -2
s for the block of tetracaine (at a concentration of 30 ,uM)
to reach completion. Hence, in the measurement of hoo, the
prepulse duration was set for 5 s. However, during the
voltage-ramp protocol the total duration was set for 15 s from
-130 mV to +50 mV. It is likely that even a quasi-steady
state cannot be achieved at -70 mV under these conditions
(i.e., 12 mV/s of ramp speed). In addition, if the activation
gate, when closed, prevented the charged form of tetracaine
from entering the pore (and the tetracaine binding site was
assumed to be within the permeation pathway), such a phe-
nomenon would be expected because the activation gate fluc-
tuated between open and closed states at voltages of <-40
mV, and the access of charged tetracaine might be limited.
It is likely that the charged form of tetracaine has greater
access to open channels than to their closed counterparts. As
channel activation reaches its completion around -40 mV
(Wang and Wang, 1994) so does the block of tetracaine reach
its quasi-steady state under the voltage-ramp protocol (Fig.
5 B). This explanation is also consistent with the observation
shown in Fig. 8 B. As the Na+ channel reaches its activation
threshold, N-butyl tetracaine QA can access its receptor
when the channel is in its open form. The availability of the
open form becomes a rate-limiting step for the charged
drug during the voltage-ramp protocol between -75 and
-50 mV, despite the fact that the internal concentration
of N-butyl tetracaine QA may continue to increase after
5 min of treatment.
Are there overlapping binding sites for the
inactivation enhancer and the
open-channel blocker?
The binding site for the inactivation enhancer probably lies
within the Na+ permeation pathway, as discussed above.
Open-channel blockers such as cocaine, bupivacaine, and
amphipathic QA compounds are also likely to be within the
pore (e.g., Wang et al., 1991). Voltage-dependent blocking
characteristics indicate that the binding site for these open-
channel blockers is located about halfway into the electric
field. Furthermore, external Na+ ions reduce the potency of
open-channel blockers, again probably through electrostatic
effects. Given that the voltage-dependent blocking charac-
teristics of inactivation enhancers parallel the h. curve, it is
not possible to determine directly the relative location of their
binding site within the electric field. Nonetheless, the avail-
able evidence shows that tetracaine is a dual blocker that
binds preferentially with the inactivated state but can also
block the open channel. For example, at pH 6.2, the strong
rectification of the tetracaine block at the 0- to 50-mV range
(Fig. 6 B) indicates that positively charged tetracaine is
driven into the open-channel pore when the membrane po-
tential is depolarized. This phenomenon is commonly docu-
mented for open-channel blockers. A similar rectification
was found for the QA derivative of tetracaine within this
voltage range (Fig. 8 B). Finally, in bilayer experiments tet-
racaine induced long-lasting closures and reduced the single-
channel conductance of rabbit muscle BTX-modified Na+
channels (particularly at more depolarized potentials, data
not shown). This observation is consistent with those in pre-
viously reported bilayer studies of procaine (Moczydlowski
et al., 1986). Unfortunately, our initial attempts to study the
detailed action of tetracaine in single BTX-modified muscle
Na+ channels in bilayers were hampered by the frequent
disappearance of single Na+ channels in the presence of tet-
racaine. Furthermore, the induced closures by tetracaine
were relatively long and highly variable from channel to
channel (average mean closed time at 300 ,uM tetracaine
ranging from 1 to 8 s, which made kinetic analyses difficult).
These difficulties were reported previously for benzocaine
and procaine in the bilayer system (Moczydlowski et al.,
1986).
To explain the complicated action of tetracaine on BTX-
modified Na+ channels in GH3 cells, we apply the concepts
of the modulated receptor hypothesis (Hille, 1977, 1992b)
and suggest that overlapping binding sites for inactivation
enhancers and open- channel blockers are present for all LA
drugs and QA compounds. In the absence of evidence for two
clearly separate tetracaine binding sites in BTX-modified
Na+ channels, as determined by the Hill coefficient of -1
(Fig. 4), the following simple kinetic scheme with a single
binding site can be used to describe our results.
C = O
* 4 * 4
C* 0*
(Scheme 1)
where 0 is the open state, C is the closed state (which in-
cludes the resting and inactivated states), and * is tetracaine.
The C O-* 0 <-> O* pathway is proposed for open-channel
blockers (type 1 LAs) and the 0 O-> C <-> C* pathway for
inactivation enhancers (type 2 LAs). Hence, the block of
tetracaine and its mode of action are state dependent. At -70
mV, tetracaine binds to the inactivated state with a high af-
finity and "stabilizes" such a conformation upon binding.
Less binding occurs between tetracaine and the resting closed
channels or open channels. At +50 mV, inactivated channels
are forced to open (Wang and Wang, 1992a) but tetracaine
may still interact with the 0 state as an open-channel blocker.
In the presence of tetracaine, a mixture of the C* state and
the O* state probably coexists at +50 mV. It is likely that
the 0 O-> O* pathway at +50 mV elicits a fast open-channel
block by reducing single-channel conductance, as in bilayers.
Such a pathway presumably competes with the 0 O-> C C*
pathway in a mutually exclusive manner; i.e., one chan-
nel can bind only one tetracaine molecule at a time.
Separation of these two states cannot be resolved at the
macroscopic current level, nor can the pathway of C*
O* be ascertained.
Recently, Zamponi and French (1993) studied the effects
of diethylamine and phenol on single BTX-modified cardiac
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Na+ channels. They suggested that there are two separate
binding sites: one for the fast block of the open channel
(C O-> 0 O-* 0* pathway) and another for the slow block of
the closed inactivated channel (O <-- C "-C* pathway) (but
see Gingrich et al. (1993) for a one-site theory regarding
normal cardiac Na+ channels). In particular, these authors
envisioned the binding of the neutral form of the drug to a
site located in a hydrophobic environment close to the re-
ceptor near the inactivation gate. Although our results
showed that the presence of a neutral form of drug is not a
prerequisite for tetracaine binding with the inactivated chan-
nel and that the tetracaine binding site is within the Na+
permeation pathway, we were unable to exclude the two-site
theory. It may prove difficult to eliminate such a possibility
because the effects of the drug by specific and nonspecific
binding sites for neutral anesthetics, particularly at high con-
centrations, tend to be superimposed (for details see Elliott
and Haydon, 1989).
Is the common four-amino group in inactivation
enhancers Important for binding?
To address this question, it is necessary to examine the struc-
ture of open-channel blockers and inactivation enhancers.
We have noticed that all inactivation enhancers, such as ben-
zocaine, tetracaine, and procaine, contain a common four-
amino group (a three-amino group for tricaine) on the phenyl
ring, whereas the open-channel blockers such as cocaine,
bupivacaine, and amphipathic QA compounds, do not. An
exception to this rule is procainamide, which acts as an open-
channel blocker (Zamponi et al., 1993a). However, this com-
pound has an amide bond (instead of an ester bond) linked
with the phenyl ring. The planar amide bond may position
the phenyl ring at an angle that diminishes the interactions
of the four-amino group with the Na+ channel. In addition,
we omit the discussion of lidocaine as an inactivation en-
hancer because such a phenomenon is so far found only in
cardiac Na+ channels (Zamponi et al., 1993c). We have pre-
viously reported that dimethylation of the four-amino group
of benzocaine diminishes its ability to enhance inactivation
effectively. Given that a single alkylation of the four-amino
group in tetracaine does not destroy its potency in enhancing
inactivation, the preferred binding between the Na+ channel
and the four-amino group of tetracaine probably still takes
place. Unfortunately, the exact contribution of the butyl
group in tetracaine potency cannot be directly assessed, be-
cause we were unable to obtain the compound without the
butyl group. Deletion of the 4-butylamino group, however,
reduces the potency of tetracaine as an inactivation enhancer
by -100-fold (IC50 = -1.5 vs. ' 10 ,uM at -50 mV). This
result is consistent with the idea that drugs with a four-amino
group (or 4-butylamino group) on the phenyl ring can sta-
bilize the inactivated state much more efficiently than those
without such a group. If so, the 4-butylamino group of tet-
racaine may actually interact (directly or indirectly) with the
inactivation gating mechanism, such as stabilizing the inac-
tivation docking receptor and/or the inactivation "ball" when
the channel is in its inactivated state. In terms of Scheme 1,
we surmise that the interaction with the 4-butylamino group
is enhanced (i.e., as an inactivation enhancer) when the BTX-
modified Na+ channel is in its inactivated state. For open
channels at the more depolarized voltage, this interaction
with the 4-butylamino group of tetracaine is weakened (i.e.,
as an open-channel blocker), probably as a result of confor-
mational changes at the tetracaine binding site.
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